165 related articles for article (PubMed ID: 38662349)
1. High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
Jessop SJ; Fuentos-Bolanos N; Mayoh C; Dolman MEM; Tax G; Wong-Erasmus M; Ajuyah P; Tyrell V; Marshall GM; Ziegler DS; Lau LMS
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2061. PubMed ID: 38662349
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
3. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
[TBL] [Abstract][Full Text] [Related]
4. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Wu X; Zhang J; Chen Q; Zhou L; Li M; Qiu H; Sun A; Wu D
Br J Haematol; 2020 Jun; 189(5):e200-e204. PubMed ID: 32242923
[No Abstract] [Full Text] [Related]
6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
7. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
8. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
Dillon R; Potter N; Freeman S; Russell N
Br J Haematol; 2021 Apr; 193(2):231-244. PubMed ID: 33058194
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
10. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
Mamez AC; Raffoux E; Chevret S; Lemiale V; Boissel N; Canet E; Schlemmer B; Dombret H; Azoulay E; Lengliné E
Leuk Lymphoma; 2016 Oct; 57(10):2281-8. PubMed ID: 26849624
[TBL] [Abstract][Full Text] [Related]
12. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
14. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J; Metzner M; Boucher R; Jackson A; Hopkins L; Pavlu J; Tholouli E; Drummond M; Peniket A; Bishop R; Fox S; Vyas P; Craddock C
Br J Haematol; 2022 Jan; 196(2):368-373. PubMed ID: 34490623
[TBL] [Abstract][Full Text] [Related]
15. Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.
Diamantopoulos PT; Giannakopoulou N; Hatzidavid S; Viniou NA
Oncol Res Treat; 2019; 42(10):532-535. PubMed ID: 31480052
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Kayser S; Hills RK; Langova R; Kramer M; Guijarro F; Sustkova Z; Estey EH; Shaw CM; Ráčil Z; Mayer J; Zak P; Baer MR; Brunner AM; Szotkowski T; Cetkovsky P; Grimwade D; Walter RB; Burnett AK; Ho AD; Ehninger G; Müller-Tidow C; Platzbecker U; Thiede C; Röllig C; Schulz A; Warsow G; Brors B; Esteve J; Russell NH; Schlenk RF; Levis MJ
Br J Haematol; 2021 Mar; 192(5):832-842. PubMed ID: 33529373
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
[TBL] [Abstract][Full Text] [Related]
18. A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ; Kloss R; Ahmed-Khan M; Carmona-Pires F; Okam N; Weeraddana P; Dharmaratna D; Dandwani M; Moin K
Hematology; 2023 Dec; 28(1):2196482. PubMed ID: 37036019
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia.
Stone RM; O'Donnell MR; Sekeres MA
Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
[TBL] [Abstract][Full Text] [Related]
20. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
